Skip to content

Clinical Study on cross-channel multi-drilling core decompression in the treatment of early-stage nontraumatic osteonecrosis of the femoral head

Clinical Study on the Three-Stage Integrated Chinese and Western Medicine Treatment for Femoral Head Necrosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107648
Enrollment
Unknown
Registered
2025-08-15
Start date
2022-01-26
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nontraumatic osteonecrosis of the femoral head

Interventions

natural course group:Conservative treatment
conventional multi-drilling core decompression group:conventional multi-drilling core decompression
Conventional Single-Hole Core Decompression:Conventional single-bore large-diameter core decompression
cross channel multi-drilling core decompression group:cross channel multi-drilling core decompression
cross channel multi-drilling core decompression combined with PRP injection group:cross channel multi-drilling core decompression combined with PRP injection

Sponsors

Wendeng Orthopaedic Hospital of Shandong Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria outlined in the Clinical Guidelines for the Diagnosis and Treatment of Adult Osteonecrosis of the Femoral Head (2016); 2.Aged between 18 and 60 years; 3. Willing to undergo treatment and complete follow-up assessments; 4. No contraindications or history of allergies to the trial medications; 5.Diagnosed with early-stage non-traumatic osteonecrosis of the femoral head (ONFH, Ficat stage I-II).

Exclusion criteria

Exclusion criteria: 1. Accompanied by systemic immune disorders; 2. There are language and mental disorders that prevent effective cooperation; 3. Hip joint deformities, tumors, surgical history, and fracture history; 4. Inflammatory arthritis, including rheumatoid arthritis, purulent arthritis, and gouty arthritis, etc; 5. Individuals with severe abnormalities in heart, lung, liver, and kidney function, infections, and mental illnesses; 6. Patients with coagulation dysfunction; 7. Individuals who have received steroid treatment within the past 6 months or have continued exposure to high-risk factors such as alcohol and hormones; 8. Pregnant.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale/Score;Harris Hip Score;Total Hip Replacement Conversion Rate;

Countries

China

Contacts

Public ContactGao Guangling

Wendeng Orthopaedic Hospital of Shandong Province

zhaojinwei778@163.com+86 135 6217 9926

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026